Clinical Trials Logo

HER2+/HR+ Breast Cancer clinical trials

View clinical trials related to HER2+/HR+ Breast Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT04224272 Active, not recruiting - Clinical trials for HER2+/HR+ Breast Cancer

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Start date: June 10, 2020
Phase: Phase 2
Study type: Interventional

This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in combination with palbociclib plus fulvestrant. Eligible patients include those with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-positive breast cancer.